BCTX (BriaCell Therapeutics Corp.) Gunggung Aset Perusahaan

The linear price action on the total assets chart for BriaCell Therapeutics (BCTX), which currently stands at 22.61, is subject to geopolitical instability that is hindering global trials and component deliveries. High costs associated with the final stages of immunotherapy development are placing significant pressure on financial stability. Looking ahead, the business capitalization will rely on the implementation of the Bria-IMT platform for the treatment of advanced breast cancer.

Aset Agregat Perusahaan BriaCell Therapeutics Corp. (BCTX): kanggo periode 04.07.2022 - 30.10.2026

Rincian metrik keuangan lan pasar BriaCell Therapeutics Corp (BCTX)

- kuotasi lan prakiraan analis:

Kurs saham briacell.com|BCTX - Prakiraan konsensus analis

- indikator valuasi pasar bisnis:

Biji pasar BriaCell Corp|BCTX - Nilai Perusahaan

- rincian nilai buku perusahaan:

Nilai Buku saben Saham BriaCell|BCTX - Nilai Buku Perusahaan|Rasio Kapitalisasi marang Nilai Buku briacell.com|BCTX - Total Aset Perusahaan

- indikator beban utang lan likuiditas:

Rasio Total Utang marang Ekuitas BriaCell Therapeutics|BCTX - Utang jangka dawa marang modal|Kewajiban jangka cendhak marang modal BriaCell Corp|BCTX - Utang perusahaan|Rasio utang marang aset resik BriaCell Corp|BCTX - Kewajiban jangka dawa perusahaan|Silihan lan utang jangka cendhak perusahaan BriaCell|Indikator likuiditas cepet briacell.com

- rincian bathi lan kelipatan pasar:

BCTX - Bathi resik perusahaan

Analisis dhasar perusahaan:briacell.com (BCTX)

BriaCell Therapeutics (BCTX) development of exclusive immunotherapeutic vaccines requires significant resources, which is reflected in the dynamics of total assets and liabilities. This metric, reconstructed via a reverse return on assets (ROA) calculation, allows for an assessment of the issuer's actual material base, while an analysis of total assets in conjunction with debt load reveals the company's true liquidity.

Pesaing wigati